Developer docs
API playgroundTry for free, no card

Search company profiles

ooo bionorica

Full company profile

uuid02mdqq2

Namestring
ooo bionorica
Legal namestring
OOO Bionorika (ООО «Бионорика»)
Websiteurl
bionorica.ru
Company typeenum
Private
Founded yearint
1933
Descriptiontext

Bionorica SE is a German family-owned pharmaceutical company founded in 1933 by Joseph Popp in Nuremberg, now controlled by the second-generation owner Prof. Dr. Michael A. Popp. The company specializes in evidence-based phytopharmaceuticals (plant-based medicines) across three therapeutic areas: respiratory conditions (Sinupret, Sinupret extract, Bronchipret, Tonsilgon N, Tonsipret), urinary tract diseases (Canephron N), and gynecological disorders (Cyclodinon, Mastodinon, Klimadynon), with dronabinol as an adjacent cannabis-based offering for seriously ill patients. All products are developed under the proprietary Phytoneering concept — a vertically integrated process combining seed selection, cultivation, genetic plant identification, NIR-based field analysis, triple quadrupole and time-of-flight mass spectrometry, and clinical research — exclusively owned by Bionorica SE.

The company generates revenue primarily through OTC pharmacy sales of finished phytopharmaceutical products, with global OTC sales of EUR 272 million in 2017 and consolidated revenue exceeding EUR 300 million in 2018. A secondary B2B stream sells standardized plant extracts through wholly-owned subsidiaries Phytoneering Extracts Solutions GmbH (Neumarkt, Germany) and Phytoneering Extracts Solutions S.L. (Consell, Mallorca). Distribution combines pharmacy retail across 50+ countries with the proprietary Фитотека (Phytothek) science-educational pharmacy format (~1,000 units worldwide; 55 in Russia via Unipharm partnership; ~900 in Germany) and a 300+ medical representative field force covering 70+ Russian cities. The company is funded internally with a 79% equity ratio (2017) and reported EUR 14.9M of growth investment in 2017 alongside >EUR 100M of headquarters capex over five years.

Primary customers are healthcare professionals (physicians and pharmacists) who prescribe or recommend Bionorica products, and end-consumer patients seeking OTC plant-based alternatives for common conditions including rhinosinusitis, bronchitis, tonsillitis, cystitis, pyelonephritis, menstrual disorders, mastopathy, and menopausal symptoms. Bionorica is the No. 1 phytopharmaceutical manufacturer in Germany, market leader in several countries, and operates a global research network of 500+ universities, clinics, and institutes. OOO Bionorika is the wholly-owned Russian subsidiary (LLC, Moscow), part of Bionorica SE's group structure.

Short descriptiontext

Bionorica SE is a German family-owned pharmaceutical company developing evidence-based plant-based (phytopharmaceutical) medicines for respiratory, urinary tract, and gynecological conditions. It sells OTC products such as Sinupret, Canephron, and Bronchipret through pharmacies in 50+ countries, with OOO Bionorika as its Russian subsidiary.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersNeumarkt, Germany
HQ citystring
Neumarkt
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
phytopharmaceutical products, herbal medicinal products, plant-based pharmaceuticals, respiratory therapeutics, gynecological treatments
Industry4 codes
PRIMARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYHLAIADAC
Allergy, Sinus & Respiratory (Non-Asthma)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIADAB
Cold, Flu & Cough Remedies
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIADAG
Sleep, Stress & Mood Support
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Phytopharmaceuticals
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Phytopharmaceutical Product Sales
TypeHardware Sales
Description

Bionorica generates revenue primarily through the sale of its OTC (over-the-counter) and prescription plant-based pharmaceutical products. Global OTC sales in 2017 reached EUR 272 million. Revenue is distributed across three therapeutic segments: respiratory, urological, and gynecological. Russia and Germany are the strongest markets.

bionorica.ru
2Dronabinol (Cannabis-based)
TypeHardware Sales
Description

Sales of dronabinol for improving quality of life of seriously ill patients. Global dronabinol sales in 2017 were approximately EUR 13.6 million, more than double the previous year, benefiting from German legislative changes allowing cannabis-based medication reimbursement.

bionorica.ru
3Phytoneering Extracts (B2B)
TypeLicensing Royalties
Description

Phytoneering Extracts Solutions GmbH and S.L. produce and sell standardized plant extracts to other pharmaceutical manufacturers, generating revenue through ingredient supply agreements.

bionorica.ru
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Phytoneering
Description

Proprietary concept combining plant science and pharmaceutical engineering for developing plant-based medicines. Trademarked technology owned exclusively by Bionorica SE.

bionorica.ru
Core offering1 text field

OOO Bionorica is the Russian subsidiary of Bionorica SE, a German family-owned pharmaceutical company that develops, manufactures, and distributes evidence-based plant-based (phytopharmaceutical) medicines. Its product portfolio spans three therapeutic segments: respiratory tract treatments (Sinupret, Bronchipret, Tonsilgon N, Tonsipret), urinary tract treatments (Canephron N), and gynecological treatments (Cyclodinon, Mastodynon, Klimadynon). The company produces these medicines using its proprietary "Phytoneering" concept that combines plant cultivation, quality control, and clinical research, and sells them primarily as OTC products through pharmacies in Russia, Germany, and 50+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Global sales grew 17.6% in 2017 vs 2016
+6 more records
Product overview1 text field

Bionorica is a German pharmaceutical company specializing in evidence-based plant-based (phytopharmaceutical) medicines. The product portfolio consists of three main therapeutic areas: respiratory tract treatments (Синупрет®, Синупрет® экстракт, Бронхипрет®, Тонзилгон® Н, Тонзипрет®), urinary tract treatments (Канефрон® Н), and gynecological treatments (Циклодинон®, Мастодинон®, Климадинон®). All products are developed using the proprietary 'Phytoneering' concept, which combines traditional phytotherapy with modern pharmaceutical research and quality standards. The company positions itself as a leader in scientifically-backed herbal medicines, with products available in various forms including tablets, drops, syrups, and lozenges, targeting both adult and pediatric populations.

Product and service6 records
1Sinupret® (Синупрет®)
CategoryRespiratory Medicines
2Sinupret® extract (Синупрет® экстракт)
CategoryRespiratory Medicines
3Bronchipret® (Бронхипрет®)
CategoryRespiratory Medicines
4Tonsilgon® N (Тонзилгон® Н)
CategoryRespiratory Medicines
5Tonsipret® (Тонзипрет®)
CategoryRespiratory Medicines
6Cyclodinon® (Циклодинон®)
CategoryGynecological Medicines
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-09-14
Description

Bionorica partnered with the Unipharm pharmacy chain to launch the 'Фитотека' (Phytothek) science-educational pharmacy format in Russia. The first Russian Фитотека opened at the 'Island of Dreams' shopping center in Moscow in September 2020. Unipharm provides the pharmacy retail presence and professional pharmacist consultations; Bionorica provides the concept, training, and product range. There are 55 Фитотеки in Russia as of 2020.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

In 2017, the M. Popp Institute was founded at Innsbruck University as part of the Phytovalley® Tyrol initiative. The institute aims to position Innsbruck and the region as a center for modern scientific research on medicinal herbs. Research staff of approximately 20 scientists and students are jointly funded by the Tyrol state administration and Prof. Popp.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bionorica operates a global research network comprising more than 500 leading institutes, clinics, and universities worldwide. Research collaborations span plant ingredient analysis, clinical trials, and R&D activities. Part of the Phytovalley® Tyrol initiative with Innsbruck University.

4Phytoneering Extracts Solutions GmbH
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Wholly-owned Bionorica subsidiary manufacturing standardized plant extracts. Produces extracts at Neumarkt, Germany and Mallorca, Spain facilities. Sells extracts to other pharmaceutical manufacturers worldwide.

bionorica.ru
5Phytoneering Extracts Solutions S.L.
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Bionorica subsidiary based in Конселл, Mallorca. Uses new cultivation and processing techniques for medicinal plants under the Phytoneering philosophy. Climate and soil conditions on Mallorca are optimized for highest quality raw materials.

bionorica.ru
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German family-owned phytopharmaceutical company and one of the world's largest plant-based medicine manufacturers (e.g., Tebonin, Crataegutt). Closest direct peer to Bionorica in product category, German heritage, OTC respiratory and circulatory positioning, and family-ownership structure.

2Biologische Heilmittel Heel GmbH
TypeDirect peer
Description

German manufacturer of plant-based and homeopathic medicines with global presence across respiratory, gynecology, and pain indications. Highly comparable to Bionorica in business model, German HQ, and physician-detail-led phytopharmaceutical portfolio.

TypeDirect peer
Description

German family-owned producer of plant-based OTC medicines (Prospan for coughs, Sinuc, Isla-Moos). Directly comparable mid-sized German phytopharma focused on respiratory and ENT, similar GTM through medical reps and pharmacy channels.

4Steigerwald Arzneimittelwerk GmbH
TypeDirect peer
Description

German plant-based pharma company (part of Bayer Consumer Health) producing Iberogast and other phytopharmaceuticals for gastrointestinal and related indications. Comparable in phytopharma heritage and HCP-driven distribution.

TypeDirect peer
Description

Swiss plant-based medicine manufacturer (Echinaforce, A.Vogel tinctures) with strong pharmacy distribution across Europe. Comparable as a mid-sized European player in evidence-based herbal OTC medicines with similar therapeutic-area coverage in respiratory and women's health.

TypeBroad incumbent
Description

Global pharma and consumer health giant with significant phytopharmaceutical and OTC portfolio (e.g., Iberogast via Steigerwald, Aspirin, Bepanthen). Broader incumbent competing in the same pharmacy channels and respiratory/pain OTC categories as Bionorica.

TypeDirect peer
Description

German mid-sized manufacturer of plant-based OTC medicines (e.g., Cefakliman, Venen-Tropfen). Comparable as a smaller German phytopharma peer with similar regulatory positioning and physician-targeted marketing.

TypeBroad incumbent
Description

German generics and consumer health company with broad OTC portfolio including phytopharmaceuticals (e.g., Grippostad, Hoggar). Comparable as a German-headquartered competitor in OTC pharmacy channels, though broader and more generic-focused than Bionorica.

TypeRegional player
Description

Leading Russian pharmaceutical manufacturer with broad OTC and prescription portfolio including plant-based products. Comparable as the dominant Russian-market competitor to OOO Bionorica in respiratory and women's health OTC categories served through pharmacy chains.

TypeDirect peer
Description

Austrian pharma company with phytopharmaceutical and OTC focus, including respiratory and women's health brands. Comparable as a mid-sized European plant-based pharma peer operating across similar therapeutic niches and pharmacy-retelivery models.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration8 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ooo bionorica

Phytopharmaceuticalsbionorica.ru

Bionorica SE is a German family-owned pharmaceutical company developing evidence-based plant-based (phytopharmaceutical) medicines for respiratory, urinary tract, and gynecological conditions. It sells OTC products such as Sinupret, Canephron, and Bronchipret through pharmacies in 50+ countries, with OOO Bionorika as its Russian subsidiary.

What ooo bionorica does

Bionorica SE is a German family-owned pharmaceutical company founded in 1933 by Joseph Popp in Nuremberg, now controlled by the second-generation owner Prof. Dr. Michael A. Popp. The company specializes in evidence-based phytopharmaceuticals (plant-based medicines) across three therapeutic areas: respiratory conditions (Sinupret, Sinupret extract, Bronchipret, Tonsilgon N, Tonsipret), urinary tract diseases (Canephron N), and gynecological disorders (Cyclodinon, Mastodinon, Klimadynon), with dronabinol as an adjacent cannabis-based offering for seriously ill patients. All products are developed under the proprietary Phytoneering concept — a vertically integrated process combining seed selection, cultivation, genetic plant identification, NIR-based field analysis, triple quadrupole and time-of-flight mass spectrometry, and clinical research — exclusively owned by Bionorica SE.

The company generates revenue primarily through OTC pharmacy sales of finished phytopharmaceutical products, with global OTC sales of EUR 272 million in 2017 and consolidated revenue exceeding EUR 300 million in 2018. A secondary B2B stream sells standardized plant extracts through wholly-owned subsidiaries Phytoneering Extracts Solutions GmbH (Neumarkt, Germany) and Phytoneering Extracts Solutions S.L. (Consell, Mallorca). Distribution combines pharmacy retail across 50+ countries with the proprietary Фитотека (Phytothek) science-educational pharmacy format (~1,000 units worldwide; 55 in Russia via Unipharm partnership; ~900 in Germany) and a 300+ medical representative field force covering 70+ Russian cities. The company is funded internally with a 79% equity ratio (2017) and reported EUR 14.9M of growth investment in 2017 alongside >EUR 100M of headquarters capex over five years.

Primary customers are healthcare professionals (physicians and pharmacists) who prescribe or recommend Bionorica products, and end-consumer patients seeking OTC plant-based alternatives for common conditions including rhinosinusitis, bronchitis, tonsillitis, cystitis, pyelonephritis, menstrual disorders, mastopathy, and menopausal symptoms. Bionorica is the No. 1 phytopharmaceutical manufacturer in Germany, market leader in several countries, and operates a global research network of 500+ universities, clinics, and institutes. OOO Bionorika is the wholly-owned Russian subsidiary (LLC, Moscow), part of Bionorica SE's group structure.

ooo bionorica firmographics

Firmographics
Name
ooo bionorica
Legal name
OOO Bionorika (ООО «Бионорика»)
Website
https://bionorica.ru
Company type
Private
Founded year
1933
Operating status
Operating
Short description
Bionorica SE is a German family-owned pharmaceutical company developing evidence-based plant-based (phytopharmaceutical) medicines for respiratory, urinary tract, and gynecological conditions. It sells OTC products such as Sinupret, Canephron, and Bronchipret through pharmacies in 50+ countries, with OOO Bionorika as its Russian subsidiary.
Ownership category
akta.pro rank

ooo bionorica industry classification

Industry
Product category
Phytopharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYHLAIADAC
Allergy, Sinus & Respiratory (Non-Asthma)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIADAB
Cold, Flu & Cough Remedies
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIADAG
Sleep, Stress & Mood Support
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • Phytopharmaceutical products
  • Herbal medicinal products
  • Plant-based pharmaceuticals
  • Respiratory therapeutics
  • Gynecological treatments

Where ooo bionorica is headquartered

Location

Headquarters

HQ city
Neumarkt
HQ country
Germany
HQ region
Europe

Offices4 records

Markets served

ooo bionorica business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

  1. Phytopharmaceutical Product Sales: Bionorica generates revenue primarily through the sale of its OTC (over-the-counter) and prescription plant-based pharmaceutical products. Global OTC sales in 2017 reached EUR 272 million. Revenue is distributed across three therapeutic segments: respiratory, urological, and gynecological. Russia and Germany are the strongest markets.
  2. Dronabinol (Cannabis-based): Sales of dronabinol for improving quality of life of seriously ill patients. Global dronabinol sales in 2017 were approximately EUR 13.6 million, more than double the previous year, benefiting from German legislative changes allowing cannabis-based medication reimbursement.
  3. Phytoneering Extracts (B2B): Phytoneering Extracts Solutions GmbH and S.L. produce and sell standardized plant extracts to other pharmaceutical manufacturers, generating revenue through ingredient supply agreements.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

ooo bionorica product offering

Product offering

Core offering

OOO Bionorica is the Russian subsidiary of Bionorica SE, a German family-owned pharmaceutical company that develops, manufactures, and distributes evidence-based plant-based (phytopharmaceutical) medicines. Its product portfolio spans three therapeutic segments: respiratory tract treatments (Sinupret, Bronchipret, Tonsilgon N, Tonsipret), urinary tract treatments (Canephron N), and gynecological treatments (Cyclodinon, Mastodynon, Klimadynon). The company produces these medicines using its proprietary "Phytoneering" concept that combines plant cultivation, quality control, and clinical research, and sells them primarily as OTC products through pharmacies in Russia, Germany, and 50+ countries.

Product overview

Bionorica is a German pharmaceutical company specializing in evidence-based plant-based (phytopharmaceutical) medicines. The product portfolio consists of three main therapeutic areas: respiratory tract treatments (Синупрет®, Синупрет® экстракт, Бронхипрет®, Тонзилгон® Н, Тонзипрет®), urinary tract treatments (Канефрон® Н), and gynecological treatments (Циклодинон®, Мастодинон®, Климадинон®). All products are developed using the proprietary 'Phytoneering' concept, which combines traditional phytotherapy with modern pharmaceutical research and quality standards. The company positions itself as a leader in scientifically-backed herbal medicines, with products available in various forms including tablets, drops, syrups, and lozenges, targeting both adult and pediatric populations.

Differentiator

Problem solved

Functional benefit

Brands

  • Phytoneering: Proprietary concept combining plant science and pharmaceutical engineering for developing plant-based medicines. Trademarked technology owned exclusively by Bionorica SE.

Products and services

  • Sinupret® (Синупрет®)
  • Sinupret® extract (Синупрет® экстракт)
  • Bronchipret® (Бронхипрет®)
  • Tonsilgon® N (Тонзилгон® Н)
  • Tonsipret® (Тонзипрет®)
  • Cyclodinon® (Циклодинон®)

Quantifiable outcome

  • Global sales grew 17.6% in 2017 vs 2016
  • +6 more outcomes

Companies that use ooo bionorica

Customer profile

Named customers7 records

Segments2 records

Ideal customer profiles2 records

ooo bionorica technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration8 records

Feature6 records

ooo bionorica partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Unipharm (Юнифарма)coreChannel Partner/ Reseller/ Distributor · 14 September 2020Bionorica partnered with the Unipharm pharmacy chain to launch the 'Фитотека' (Phytothek) science-educational pharmacy format in Russia. The first Russian Фитотека opened at the 'Island of Dreams' shopping center in Moscow in September 2020. Unipharm provides the pharmacy retail presence and professional pharmacist consultations; Bionorica provides the concept, training, and product range. There are 55 Фитотеки in Russia as of 2020.
  • Leopold Franzens University of InnsbruckcoreStrategic or Co-development Partner · 1 January 2017In 2017, the M. Popp Institute was founded at Innsbruck University as part of the Phytovalley® Tyrol initiative. The institute aims to position Innsbruck and the region as a center for modern scientific research on medicinal herbs. Research staff of approximately 20 scientists and students are jointly funded by the Tyrol state administration and Prof. Popp.
  • 500+ Global Research Institutions (Universities, Clinics, Institutes)coreStrategic or Co-development PartnerBionorica operates a global research network comprising more than 500 leading institutes, clinics, and universities worldwide. Research collaborations span plant ingredient analysis, clinical trials, and R&D activities. Part of the Phytovalley® Tyrol initiative with Innsbruck University.
  • Phytoneering Extracts Solutions GmbHcoreOEM/ Whitelabel/ Licensing PartnerWholly-owned Bionorica subsidiary manufacturing standardized plant extracts. Produces extracts at Neumarkt, Germany and Mallorca, Spain facilities. Sells extracts to other pharmaceutical manufacturers worldwide.
  • Phytoneering Extracts Solutions S.L.coreOEM/ Whitelabel/ Licensing PartnerBionorica subsidiary based in Конселл, Mallorca. Uses new cultivation and processing techniques for medicinal plants under the Phytoneering philosophy. Climate and soil conditions on Mallorca are optimized for highest quality raw materials.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

ooo bionorica competitors and assessment

Company assessment

Direct peers

  • Dr. Willmar Schwabe GmbH & Co. KG: German family-owned phytopharmaceutical company and one of the world's largest plant-based medicine manufacturers (e.g., Tebonin, Crataegutt). Closest direct peer to Bionorica in product category, German heritage, OTC respiratory and circulatory positioning, and family-ownership structure.
  • Biologische Heilmittel Heel GmbH: German manufacturer of plant-based and homeopathic medicines with global presence across respiratory, gynecology, and pain indications. Highly comparable to Bionorica in business model, German HQ, and physician-detail-led phytopharmaceutical portfolio.
  • Engelhard Arzneimittel GmbH & Co. KG: German family-owned producer of plant-based OTC medicines (Prospan for coughs, Sinuc, Isla-Moos). Directly comparable mid-sized German phytopharma focused on respiratory and ENT, similar GTM through medical reps and pharmacy channels.
  • Steigerwald Arzneimittelwerk GmbH: German plant-based pharma company (part of Bayer Consumer Health) producing Iberogast and other phytopharmaceuticals for gastrointestinal and related indications. Comparable in phytopharma heritage and HCP-driven distribution.
  • A. Vogel AG: Swiss plant-based medicine manufacturer (Echinaforce, A.Vogel tinctures) with strong pharmacy distribution across Europe. Comparable as a mid-sized European player in evidence-based herbal OTC medicines with similar therapeutic-area coverage in respiratory and women's health.
  • Cesra Arzneimittel GmbH & Co. KG: German mid-sized manufacturer of plant-based OTC medicines (e.g., Cefakliman, Venen-Tropfen). Comparable as a smaller German phytopharma peer with similar regulatory positioning and physician-targeted marketing.
  • Kwizda Pharma GmbH: Austrian pharma company with phytopharmaceutical and OTC focus, including respiratory and women's health brands. Comparable as a mid-sized European plant-based pharma peer operating across similar therapeutic niches and pharmacy-retelivery models.

Broad incumbents

  • Bayer AG (Consumer Health): Global pharma and consumer health giant with significant phytopharmaceutical and OTC portfolio (e.g., Iberogast via Steigerwald, Aspirin, Bepanthen). Broader incumbent competing in the same pharmacy channels and respiratory/pain OTC categories as Bionorica.
  • Stada Arzneimittel AG: German generics and consumer health company with broad OTC portfolio including phytopharmaceuticals (e.g., Grippostad, Hoggar). Comparable as a German-headquartered competitor in OTC pharmacy channels, though broader and more generic-focused than Bionorica.

Regional players

  • Pharmstandard JSC: Leading Russian pharmaceutical manufacturer with broad OTC and prescription portfolio including plant-based products. Comparable as the dominant Russian-market competitor to OOO Bionorica in respiratory and women's health OTC categories served through pharmacy chains.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ooo bionorica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ooo bionorica leadership team

Management profile

Number of profiles

Profiles1 record

ooo bionorica subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

ooo bionorica funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ooo bionorica M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ooo bionorica

What does ooo bionorica do?

OOO Bionorica is the Russian subsidiary of Bionorica SE, a German family-owned pharmaceutical company that develops, manufactures, and distributes evidence-based plant-based (phytopharmaceutical) medicines. Its product portfolio spans three therapeutic segments: respiratory tract treatments (Sinupret, Bronchipret, Tonsilgon N, Tonsipret), urinary tract treatments (Canephron N), and gynecological treatments (Cyclodinon, Mastodynon, Klimadynon). The company produces these medicines using its proprietary "Phytoneering" concept that combines plant cultivation, quality control, and clinical research, and sells them primarily as OTC products through pharmacies in Russia, Germany, and 50+ countries.

Is ooo bionorica a public or private company?

ooo bionorica is a private company. It is classified as family owned and is currently operating.

When was ooo bionorica founded?

ooo bionorica was founded in 1933.

Where is ooo bionorica based?

ooo bionorica is headquartered in Neumarkt, Germany, in the Europe region.

How does ooo bionorica make money?

Three revenue lines are on record. Phytopharmaceutical Product Sales are the primary driver. The others are dronabinol (Cannabis-based) and phytoneering Extracts (B2B).

Who are ooo bionorica's main competitors?

Direct peers on record are Dr. Willmar Schwabe GmbH & Co. KG, Biologische Heilmittel Heel GmbH, Engelhard Arzneimittel GmbH & Co. KG, Steigerwald Arzneimittelwerk GmbH, A. Vogel AG, Cesra Arzneimittel GmbH & Co. KG and Kwizda Pharma GmbH. Broad incumbents are Bayer AG (Consumer Health) and Stada Arzneimittel AG. Pharmstandard JSC is listed as a regional player.

Does ooo bionorica have an API?

No public API is recorded for ooo bionorica.

What industry is ooo bionorica in?

ooo bionorica's product category is Phytopharmaceuticals. Its primary akta.pro industry code is EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives, with a secondary code of HLAIADAC, Allergy, Sinus & Respiratory (Non-Asthma). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales